Drug Database
IM

immune globulin intravenous (Iveegam, Immuno / Iveegam EN)

✓ Approved

Baxter International, Inc. · Polyclonal Antibodies · Polyclonal Antibodies

What is immune globulin intravenous?

immune globulin intravenous is a polyclonal antibodies developed by Baxter International, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesIveegam, Immuno, Iveegam EN
CompanyBaxter International, Inc.
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Baxter International, Inc.

Therapeutic Indications

immune globulin intravenous is developed for 5 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Immune system disordersSelective IgG subclass deficiency✓ Approved
Infections and infestationsBorna virus infection✓ Approved
Musculoskeletal and connective tissue disordersDermatomyositisPreclinical
Musculoskeletal and connective tissue disordersPolymyositisPreclinical
Musculoskeletal and connective tissue disordersJuvenile idiopathic arthritisPreclinical

Related Research Articles

PubMedThe Journal of the Association of Physicians of India2026-10-22

Risk Factors and Emerging Therapies for Immune Checkpoint Inhibitor-related Myocarditis: A Narrative Review.

Kalluri Ujjvala U, Subair Maazen Naduthra MN

Immune checkpoint inhibitors (ICIs) represent a groundbreaking development in immunotherapy, offering significant promise in the treatment of various malignancies previously considered incurable. However, despite their potential benefits, the increasing use of ICIs is associated with a spectrum of immune-related adverse events (irAEs). Myocarditis is a rare and potentially underestimated complication that represents the highest mortality rate among irAEs. The review aims to evaluate the current understanding of ICI-myocarditis (ICI-M) through providing a detailed overview of diagnostic challenges, screening strategies, and, in particular, the risk factors and evolving treatment agents beyond corticosteroids. A comprehensive literature review was conducted on PubMed, analyzing data from relevant clinical studies, case reports, preclinical models, and expert consensus guidelines. In addition, data from one ongoing clinical trial (ATRIUM trial) not yet indexed in PubMed were included to reflect emerging therapeutic developments. Despite the low incidence of ICI-M (0.06%-1%), which is likely underestimated, the mortality rate is the highest among irAEs; the most identifiable risk factors include combination therapy with ICI agents (anti-PD1 and anti-CTLA-4), preexisting cardiovascular and autoimmune diseases, use of ICIs alongside other anticancer treatments, certain tumor types, older age, and female sex. Diagnosis of the condition is faced with challenges such as nonspecific clinical features and often requires multimodal evaluation including biomarkers, imaging, and biopsy. High-dose corticosteroids remain the first-line treatment; however, steroid-refractory cases are increasingly reported. Promising second-line options include mycophenolate mofetil, antithymocyte globulin, abatacept, and tacrolimus; however, there is a lack of prospective data to support their efficacy. Studies conducted on various preclinical models highlight potential therapeutic targets such as CXCR3. ICI-M poses a significant challenge in cardio-oncology practice due to its underestimation, high mortality rate, and lack of robust clinical data evaluating standardized screening protocols and second-line treatment measures. Although several second-line agents show promise, the evidence supporting their usage is largely on the basis of expert consensus and case reports, hence representing a strong need for prospective studies offering direct comparisons. Likewise, preclinical studies show great promise in identifying the pathophysiology and potential therapeutic targets for ICI-M; however, translational studies are necessary to validate these findings.

PMID 42902674
Read full article →
PubMedThe Journal of the Association of Physicians of India2026-10-22

Safety and Effectiveness of Cyclosporine and Eltrombopag in Acquired Aplastic Anemia: Experience from a Tertiary Care Center in Eastern India.

Baul Shuvraneel S, Sharma Abhishek A, Ghosh Kaustav K, Saha Subhra Kamal SK et al.

Acquired aplastic anemia (AAA) is an immune-mediated bone marrow failure syndrome traditionally treated with antithymocyte globulin (ATG)-based immunosuppressive therapy. However, many patients-particularly older adults and those with significant comorbidities-are unable to tolerate ATG. The combination of cyclosporine (CSA) and eltrombopag (EPAG) without ATG has emerged as a potential alternative, though real-world data from India remain limited. This single-center, retrospective observational study included consecutive adult patients (n = 40; ≥18 years) with severe or very severe AAA treated with CSA and EPAG without ATG between January 2020 and December 2025, study ends December 2025. Patients had contraindications to ATG due to age and/or comorbidities. Hematologic responses were assessed at 3-6 months. Overall response rate (ORR) was defined as complete plus partial response. Safety was evaluated using CTCAE v5.0 criteria. The median age was 56.5 years, with 72.5% having severe and 27.5% very severe AAA. At 6 months, complete response was observed in 17.5% and partial response in 45%, yielding an ORR of 62.5%. Notable improvements were observed in hemoglobin, absolute neutrophil count, and platelet count (all p < 0.001). Younger age (≤60 years), fewer comorbidities (≤1), higher baseline blood counts, and severe (vs very severe) disease were significantly associated with response. Treatment was well tolerated; hepatic adverse events were mild (grade ≤2), transient, and did not necessitate treatment discontinuation. Cyclosporine combined with eltrombopag is a relatively safe and effective ATG-free therapeutic option for selected patients with acquired aplastic anemia, particularly older individuals and those with comorbidities. This regimen offers meaningful hematologic recovery with acceptable toxicity and represents a pragmatic alternative in real-world and resource-limited settings.

PMID 42902644
Read full article →
PubMedBioconjugate chemistry2026-10-22

Macrophage-Targeted Quantum Dots with Short-Wave Infrared Emission for In Vivo Breast Cancer Imaging.

Xu Fengyuan F, Lee Wonseok W, Shi Kaichi K, Saha Urbi U et al.

In vivo characterization and visualization of tumors often relies on radioactive tracers and expensive, complex equipment, which limits the frequency of analysis, throughput, and accessibility. Short-wave infrared (SWIR) fluorescence is a new nonradioisotopic imaging modality with flexible readouts at high depth and high signal-to-background contrast. Here, we report semiconductor quantum dots (QDs) with SWIR fluorescence engineered to selectively target tumor-associated macrophages (TAMs) by functionalization with the polysaccharide dextran (Dex). TAMs are often abundant in the tumor microenvironment and mediate immune suppression, angiogenesis, metastatic progression, and therapy resistance, making them important targets for in situ analysis. We compare QD-Dex probes with QDs coated with polyethylene glycol (QD-PEG) as nontargeted controls with equivalent fluorescence, hydrodynamic size, and electrostatic charge. In vitro, QD-Dex exhibited receptor-mediated uptake by cultured macrophages whereas QD-PEG uptake was only through noncompetitive passive processes. In vivo, SWIR imaging of immunocompetent mice bearing TAM-rich orthotopic 4T1 mammary tumors revealed tumor retention of QD-Dex after intravenous administration. Tumor signals for QD-PEG were much lower in comparison. Tumor signals for QD-Dex exceeded blood levels ∼2 h after injection and decayed substantially after 24 h, providing an appropriate time window for preclinical imaging studies in rodents. These findings establish baseline metrics for macrophage-targeted SWIR nanoprobes as a platform for preclinical in vivo tumor analysis without ionizing radiation.

PMID 42902939
Read full article →
PubMedFrontiers in immunology2026-10-22

Case Report: Immune-related colitis complicated by Clostridioides difficile-associated colitis.

Chen Wenjuan W, Zhang Wanqian W, Sun Chaoqun C, Meng Lin L et al.

Immune checkpoint inhibitors (ICIs) have become the standard treatment for patients with advanced microsatellite instability-high (MSI-H) gastric cancer. However, the incidence of immune-related adverse events (irAEs) has also increased accordingly. Immune-related colitis (IRC) is among the most common gastrointestinal manifestations of these irAEs. This report describes a patient with advanced MSI-H gastric cancer who received immunotherapy and developed Grade-3 IRC during treatment. The patient recovered following corticosteroid therapy. Diarrhea recurred after discontinuation of corticosteroids, a condition that may be misdiagnosed as a recurrence of IRC. Following a multidisciplinary team consultation, the patient was clinically diagnosed with Clostridioides difficile infection (CDI) based on symptoms and stool testing, and showed rapid improvement after vancomycin therapy. The patient achieved a durable complete clinical response lasting more than 5 years without further systemic anticancer therapy. This case illustrates that immunotherapy may confer long-term benefit in MSI-H advanced gastric cancer. Notably, the occurrence of immune-related adverse events coincided with sustained tumor control, suggesting a potential association that merits further exploration. However, when diarrhea recurs after discontinuation of corticosteroids, clinicians must remain highly vigilant regarding the overlap and differentiation between the reactivation of IRC and infectious colitis, the involvement of a multidisciplinary team is particularly crucial.

PMID 42903148
Read full article →
PubMedFrontiers in artificial intelligence2026-10-22

scTIME: single-cell-informed interpretable modeling of immunotherapy-associated immune states in non-small cell lung cancer.

Chen Guozhi G, You Chenqiu C, Gao Hong H, Xu Chengjie C

Immune checkpoint inhibitor response in non-small cell lung cancer (NSCLC) reflects coordinated tumor and immune states that are not fully captured by single biomarkers. We developed scTIME, an interpretable model that translates single-cell immune programs into bulk transcriptomic scores, and integrated public single-cell, T-cell receptor, transcriptomic, survival, and proteogenomic cohorts. Response modeling used two cohorts with different endpoints (40 patients) and compared six algorithms. ElasticNet was selected as a sparse reporting model, achieving a pooled five-fold out-of-fold ROC-AUC of 0.810; nested model selection yielded 0.772. Matched held-out stratification identified response-enriched scTIME groups in a direct descriptive comparison with CD274, while the fitted score emphasized cytotoxic CD8, natural killer, SPP1 macrophage, interferon-response, and antigen-presentation programs. Single-cell analyses and external projections linked these programs to CXCL10-CXCR3 recruitment, exclusion-associated states, and T-cell receptor ecology across molecular contexts. Exploratory survival and cross-omics analyses extended the framework beyond the response cohorts but were interpreted as projection rather than independent validation. Together, the results show how cell-resolved immune biology can support transparent, multi-omic biomarker development without reducing response to a single pathway. scTIME remains exploratory because model choice was post hoc, cohorts were small and clinically heterogeneous, and endpoint-matched external validation was unavailable.

PMID 42903172
Read full article →
PubMedVascular and endovascular surgery2026-10-22

Symptomatic Superior Vena Cava Lipoma Causing Near-Complete Venous Obstruction: A Case Report and Literature Review.

Ozden Yasin Y, Seferoglu Ege E

BackgroundLipomas are common benign mesenchymal tumors; however, intravascular localization is exceedingly rare. Superior vena cava (SVC) involvement represents an exceptional entity, with only a limited number of cases reported in the literature. Intravascular lipomas are frequently detected incidentally but may present with symptoms related to venous obstruction, including superior vena cava syndrome. We report a rare case of SVC-origin intravascular lipoma extending into the right brachiocephalic vein, accompanied by a focused review of previously published upper extremity cases.Case PresentationA 77-year-old male presented with facial and cervical edema, dyspnea exacerbated in the supine position, and distended cervical veins. Contrast-enhanced computed tomography revealed a 5-cm elongated, fat-attenuation mass within the SVC extending into the right brachiocephalic vein, causing near-total (approximately 99%) luminal occlusion. Transthoracic echocardiography supported the diagnosis. The patient underwent surgical resection via median sternotomy under cardiopulmonary bypass. Following longitudinal venotomy of the SVC extending to the brachiocephalic vein, the tumor-adherent to the posterior venous wall-was completely excised with preservation of vascular integrity. Primary venous repair was performed. The diagnosis of lipoma was histopathologically confirmed. The patient initially showed marked symptomatic improvement; however, on postoperative day 5, sudden-onset dyspnea necessitated reintubation, followed by multiorgan failure and death. The precise cause of the acute deterioration could not be definitively established.Literature review identified only 21 previously reported upper extremity intravenous lipomas, with this case representing the 16th involving the SVC and the oldest reported patient.ConclusionUpper extremity intravenous lipomas are rare and may lead to significant venous obstruction. Cross-sectional imaging is essential for diagnosis and surgical planning. In symptomatic patients, complete surgical excision provides definitive treatment and symptom relief. Management of incidentally detected asymptomatic cases remains controversial and should be individualized.

PMID 42902824
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about immune globulin intravenous